Search for: "Grant v. Bristol-Myers Squibb"
Results 121 - 140
of 158
Sort by Relevance
|
Sort by Date
2 Nov 2010, 1:40 am
When reviewing the grant of a preliminary injunction, this court "views the matter in light of the burdens and presumptions that will inhere at trial. [read post]
28 Sep 2010, 3:14 pm
Par Pharmaceutical Companies, Inc. et al (Patent Docs) Baraclude (Entecavir) – US: Patent infringement complaint filed following Paragraph IV certification: Bristol-Myers Squibb Co. v. [read post]
18 Aug 2010, 12:19 am
(IP Whiteboard) Australia: A tale of four amendment requests: Bristol-Myers Squibb Company v. [read post]
13 Aug 2010, 12:46 pm
See Bristol-Myers Squibb Co. v. [read post]
2 Jun 2010, 3:15 am
” Bristol-Myers Squibb Co., 326 F.3d at 1241; see Molins PLC, 48 F.3d at 1182 (“We recognize that [the withheld references] were cited eventually to the PTO and that the examiner . . . passed the reexamination application to issue thereafter. [read post]
25 Apr 2010, 5:52 pm
Bristol-Myers Squibb Co. [read post]
15 Apr 2010, 4:27 am
(EPLAW) Prevacid (Lansoprazole) – US: Takeda files patent infringement complaint against Zydus following Para IV challenge (Patent Docs) Reyataz (Atazanavir) – US: Bristol-Myer Squibb, Novartis file patent infringement suit against Teva following Para IV challenge (Patent Docs) Treximet (Sumatriptan, Naproxen) – US: POZEN enters into settlement agreement with Teva regarding Para IV patent litigation (SmartBrief) Zerit (Stavudine) – US: Promote… [read post]
24 Mar 2010, 4:45 am
(Patent Docs) Reyataz (Atazanavir): US: Patent infringement complaint filed following a Paragraph IV certification: Bristol-Myers Squibb Co. et al. v. [read post]
3 Mar 2010, 5:05 am
‘The solution lies in resources’ says FDA Commissioner Hamburg (FDA Law Blog) Products Actoplus MET (Pioglitazone) – US: Takeda files patent infringement suit against Aurobindo following Para IV certification as part of ANDA to manufacture generic Actoplus MET (Patent Docs) Advair diskus (Fluticasone, Salmeterol) – US: PTO denies PTE for Advair diskus patent; Office again clarifies that PTEs are not availabile for ‘synergistic combinations’ containing… [read post]
3 Mar 2010, 5:05 am
‘The solution lies in resources’ says FDA Commissioner Hamburg (FDA Law Blog) Products Actoplus MET (Pioglitazone) – US: Takeda files patent infringement suit against Aurobindo following Para IV certification as part of ANDA to manufacture generic Actoplus MET (Patent Docs) Advair diskus (Fluticasone, Salmeterol) – US: PTO denies PTE for Advair diskus patent; Office again clarifies that PTEs are not availabile for ‘synergistic combinations’ containing… [read post]
9 Dec 2009, 3:59 pm
(Patent Docs) (SmartBrief) (GenericsWeb) OxyContin (Oxycodone) – US: Ranbaxy admits infringement in OxyContin suit – District Court S D New York approves consent judgment between Ranbaxy and Purdue Pharma (Patent Docs) Reyataz (Atazanavir) – US: Complaint filed in Delaware: Infringement of US patent following a Paragraph IV challenge: Bristol-Myers Squibb Co. et al. v. [read post]
11 Nov 2009, 4:02 am
You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: http://duncanbucknell.com/subscribe/ Highlights this week included: EU: Generics producers: Criminal sanctions can stop counterfeit drugs (IP Watch) Prandin (Repaglinide) – US: Federal Circuit grants stay of preliminary relief pending full appellate review: Novo Nordisk v Caraco (Patently-O) General Eduardo Pisani of Bristol-Myers Squibb is… [read post]
11 Nov 2009, 4:02 am
You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: [duncanbucknell.com] Highlights this week included: EU: Generics producers: Criminal sanctions can stop counterfeit drugs (IP Watch) Prandin (Repaglinide) - US: Federal Circuit grants stay of preliminary relief pending full appellate review: Novo Nordisk v Caraco (Patently-O) General Eduardo Pisani of Bristol-Myers Squibb is the new IFPMA Director General (IP… [read post]
11 Nov 2009, 4:02 am
You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: [duncanbucknell.com] Highlights this week included: EU: Generics producers: Criminal sanctions can stop counterfeit drugs (IP Watch) Prandin (Repaglinide) - US: Federal Circuit grants stay of preliminary relief pending full appellate review: Novo Nordisk v Caraco (Patently-O) General Eduardo Pisani of Bristol-Myers Squibb is the new IFPMA Director General (IP… [read post]
2 Nov 2009, 1:24 pm
At the Wall Street Journal, Dow Jones Newswire’s Kristina Peterson addresses the Court’s denial of cert. in a drug-patent dispute between generic drug manufacturer Apotex Corp. and patent-holders Sanofi-Aventis and Bristol-Myers Squibb, while the Associated Press has coverage of the Court’s decision not to hear an appeal to stop the release of documents relating to sexual abuse lawsuits against Roman Catholic priests in… [read post]
1 Jul 2009, 7:14 am
(Patent Docs) Products Avapro (Irbesartan) – Spain: Fourth Commercial Court of Barcelona rejects preliminary injunction petition by Sanofi-Aventis and Bristol-Myers Squibb for alleged patent infringement (International Law Office) Cozaar/Hyzaar (Losartan/Hydrochlorothiazide and Losartan) –US: Teva sues FDA over generic Cozaar and Hyzaar 180-day exclusivity forfeiture and patent delisting rule (The FDA Law Blog) Eloxatin (Oxaliplatin) – US:… [read post]
10 Jun 2009, 10:00 pm
Bristol-Myers Squibb, 1998 WL 812318, at 30 (M.D. [read post]
27 Apr 2009, 9:43 am
Bristol-Myers Squibb Co., 25 No. 3 Andrews Pharmaceutical Litig. [read post]
3 Mar 2009, 5:55 am
What caught my eye, however, was the court's description of the order appealed from, viz, one granting "those parts of the motion of defendants seeking dismissal of the negligence and slander causes of action and the punitive damages claim. [read post]
15 Jan 2009, 3:35 am
Just to recap then, the High Court of Delhi recently granted an ex parte restraining order in favour of Bristol Myers Squibb restraining the defendants, Hetero Drugs (an Indian generic firm) from manufacturing, selling, distributing, advertising, exporting, offering for sale or in any manner dealing directly or indirectly in any product infringing the plaintiffs product patent covering Dasatinib, a drug used in the treatment of Chronic Myloeid Leukemia. [read post]
